Raab & Moskowitz Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$524K Hold
4,144
0.11% 134
2026
Q1
$578K Sell
4,144
-63
-1% -$8.82K 0.13% 120
2025
Q4
$516K Sell
4,207
-43
-1% -$5.23K 0.11% 135
2025
Q3
$472K Sell
4,250
-32
-0.7% -$3.64K 0.11% 137
2025
Q2
$475K Sell
4,282
-15
-0.3% -$1.6K 0.11% 134
2025
Q1
$481K Hold
4,297
0.12% 130
2024
Q4
$397K Hold
4,297
0.1% 137
2024
Q3
$360K Hold
4,297
0.09% 142
2024
Q2
$295K Sell
4,297
-150
-3% -$10K 0.08% 146
2024
Q1
$326K Hold
4,447
0.09% 142
2023
Q4
$360K Sell
4,447
-243
-5% -$18.9K 0.11% 131
2023
Q3
$351K Buy
4,690
+175
+4% +$13.5K 0.12% 124
2023
Q2
$348K Hold
4,515
0.12% 127
2023
Q1
$375K Sell
4,515
-100
-2% -$8.28K 0.14% 124
2022
Q4
$396K Buy
4,615
+68
+1% +$5.38K 0.15% 123
2022
Q3
$280K Sell
4,547
-68
-1% -$4.29K 0.12% 135
2022
Q2
$285K Buy
4,615
+68
+1% +$4.21K 0.11% 136
2022
Q1
$270K Hold
4,547
0.09% 146
2021
Q4
$330K Sell
4,547
-50
-1% -$3.44K 0.11% 137
2021
Q3
$321K Sell
4,597
-500
-10% -$35.1K 0.12% 131
2021
Q2
$351K Sell
5,097
-39
-0.8% -$2.6K 0.13% 121
2021
Q1
$331K Buy
5,136
+253
+5% +$16.3K 0.13% 123
2020
Q4
$284K Sell
4,883
-253
-5% -$15.3K 0.12% 125
2020
Q3
$324K Buy
5,136
+143
+3% +$9.92K 0.15% 111
2020
Q2
$384K Sell
4,993
-159
-3% -$12.2K 0.19% 105
2020
Q1
$385K Sell
5,152
-47
-0.9% -$3.25K 0.21% 102
2019
Q4
$337K Sell
5,199
-86
-2% -$5.6K 0.13% 125
2019
Q3
$334K Buy
5,285
+192
+4% +$12.6K 0.15% 126
2019
Q2
$344K Sell
5,093
-400
-7% -$26.3K 0.15% 128
2019
Q1
$357K Hold
5,493
0.16% 123
2018
Q4
$343K Sell
5,493
-736
-12% -$51.4K 0.17% 121
2018
Q3
$480K Sell
6,229
-347
-5% -$26.2K 0.2% 109
2018
Q2
$465K Sell
6,576
-5,080
-44% -$359K 0.22% 108
2018
Q1
$878K Sell
11,656
-940
-7% -$74.7K 0.43% 68
2017
Q4
$902K Sell
12,596
-1,285
-9% -$97.6K 0.44% 71
2017
Q3
$1.04M Sell
13,881
-575
-4% -$44K 0.5% 64
2017
Q2
$1.05M Sell
14,456
-1,849
-11% -$123K 0.52% 63
2017
Q1
$1.11M Sell
16,305
-576
-3% -$40.5K 0.58% 59
2016
Q4
$1.21M Sell
16,881
-1,494
-8% -$111K 0.66% 52
2016
Q3
$1.45M Sell
18,375
-3,541
-16% -$288K 0.82% 43
2016
Q2
$1.83M Sell
21,916
-346
-2% -$30.7K 1.04% 32
2016
Q1
$2.04M Sell
22,262
-1,070
-5% -$96.5K 1.22% 26
2015
Q4
$2.36M Sell
23,332
-1,856
-7% -$193K 1.41% 25
2015
Q3
$2.47M Buy
25,188
+601
+2% +$66.7K 1.6% 19
2015
Q2
$2.88M Buy
24,587
+2,734
+13% +$299K 1.77% 14
2015
Q1
$2.15M Buy
21,853
+1,617
+8% +$164K 1.3% 27
2014
Q4
$1.91M Sell
20,236
-1,236
-6% -$128K 1.09% 32
2014
Q3
$2.29M Buy
21,472
+981
+5% +$96.1K 1.11% 27
2014
Q2
$1.7M Buy
20,491
+410
+2% +$31.9K 0.81% 41
2014
Q1
$1.42M Buy
20,081
+75
+0.4% +$5.88K 0.79% 42
2013
Q4
$1.5M Buy
+20,006
New +$1.39M 0.86% 42

Other funds holding GILD

Raab & Moskowitz Asset Management's GILD Position: Q2 2026 in Review

Raab & Moskowitz Asset Management held its Gilead Sciences (GILD) position steady in Q2 2026 at 4,144 shares worth $524K. The position accounts for 0.11% of the portfolio, ranked #134.

Raab & Moskowitz Asset Management first reported a position in GILD in Q4 2013 and has held it in 51 quarters since. The position peaked at $2.88M in Q2 2015. 2,272 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Raab & Moskowitz Asset Management held 4,144 shares of Gilead Sciences worth $524K as of Q2 2026.
  • Raab & Moskowitz Asset Management left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.11% of Raab & Moskowitz Asset Management's portfolio in Q2 2026, its #134 holding.
  • Raab & Moskowitz Asset Management first reported a position in Gilead Sciences in Q4 2013 and has held it in 51 quarters since.
  • Raab & Moskowitz Asset Management's Gilead Sciences position peaked at $2.88M in Q2 2015.
  • 2,272 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Raab & Moskowitz Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.